# GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

> **NCT05650749** · PHASE1 · RECRUITING · sponsor: **Stephan Grupp MD PhD** · enrollment: 45 (estimated)

## Conditions studied

- Refractory Neuroblastoma
- Relapsed Neuroblastoma
- High-risk Neuroblastoma
- Retinoblastoma
- Metastatic Retinoblastoma

## Interventions

- **BIOLOGICAL:** GPC2 CAR T cells

## Key facts

- **NCT ID:** NCT05650749
- **Lead sponsor:** Stephan Grupp MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-23
- **Primary completion:** 2028-01-30
- **Final completion:** 2030-01-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-12-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05650749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05650749, "GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05650749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*